U.S. markets closed
  • S&P Futures

    4,472.00
    -2.25 (-0.05%)
     
  • Dow Futures

    34,738.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    15,503.50
    -14.25 (-0.09%)
     
  • Russell 2000 Futures

    2,225.40
    -2.50 (-0.11%)
     
  • Crude Oil

    72.58
    -0.03 (-0.04%)
     
  • Gold

    1,757.00
    +0.30 (+0.02%)
     
  • Silver

    22.84
    +0.05 (+0.20%)
     
  • EUR/USD

    1.1769
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • Vix

    18.69
    +0.51 (+2.81%)
     
  • GBP/USD

    1.3789
    -0.0008 (-0.06%)
     
  • USD/JPY

    109.8800
    +0.1620 (+0.15%)
     
  • BTC-USD

    47,860.43
    -50.92 (-0.11%)
     
  • CMC Crypto 200

    1,225.34
    -7.95 (-0.64%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,468.04
    +144.70 (+0.48%)
     

Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the 2019 Wedbush PacGrow Healthcare Conference being held August 13-14, 2019 in New York.

Details of the presentation are below:

Event:

Wedbush PacGrow Healthcare Conference

Date:

Tuesday, August 13, 2019

Location:

The Parker New York Hotel

Time:

9:45 – 10:15 AM ET

Additionally, Dr. Perros will hold 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their Wedbush representatives.

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.

Entasis Company Contact
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations Contacts
Tram Bui / Janhavi Mohite
The Ruth Group
(646) 536-7035 / 7026
tbui@theruthgroup.com
jmohite@theruthgroup.com

Media Contact
Kirsten Thomas
The Ruth Group
(508) 280-6592
kthomas@theruthgroup.com